Amylin analogues: the emerging drug class alongside GLP-1

Amylin, also known as islet amyloid polypeptide, is produced by pancreatic beta cells and co-secreted with insulin after nutrient intake. The literature describes it as a satiety signal connecting the pancreas, gastrointestinal system and central nervous system. Three functions recur across reviews of its physiology: limiting food intake through satiety signalling, slowing gastric emptying, and suppressing inappropriate postprandial glucagon secretion. These actions affect the rate at which nutrients appear in circulation, without making amylin either insulin or an incretin.

The amylin and GLP-1 axes converge on some physiological outcomes, including satiety and slower gastric emptying, but they are not identical. GLP-1 agonists act through the GLP-1 receptor and are associated, among other effects, with glucose-dependent insulinotropic signalling. Amylin acts through calcitonin-receptor complexes with receptor activity-modifying proteins and occupies a different neuroendocrine position. The research rationale is therefore not to duplicate GLP-1, but to investigate whether a second, complementary axis can add distinct satiety and postprandial-control signals.

Natural human amylin has limitations as a pharmacological molecule, including a tendency to aggregate and a short duration. Analogue development seeks to preserve amylin signalling while providing more suitable stability and pharmacokinetic characteristics. The class can be read as a sequence of generations: pramlintide as the first approved analogue, cagrilintide as a long-acting approach, and newer programmes such as petrelintide and eloralintide that broaden clinical research.

Pramlintide is a synthetic analogue of human amylin marketed as Symlin and was the first approved member of the class. Its place in amylin history is foundational: it demonstrated that signalling through this axis could be translated into a regulated medicine. At the same time, the official Symlin label reports a half-life of approximately 48 minutes in healthy individuals. This short pharmacokinetic duration is the central limitation that newer long-acting analogues seek to address. NCT00229658 subsequently documented Symlin use in a post-marketing observational setting among insulin-using people with type 1 or type 2 diabetes.

Pramlintide should not be conflated with newer analogues in development or treated as automatic evidence for their efficacy. It does, however, provide two useful reference points: it confirms that amylin is a pharmacologically accessible target and highlights the importance of duration of action. The next generation does not merely change the name; it seeks to alter pharmacokinetics and investigate different populations and combinations.

Cagrilintide is a long-acting amylin analogue studied clinically both alone and with semaglutide. A 2021 Phase 1 publication assessed safety, tolerability, pharmacokinetics and pharmacodynamics, while later Phase 2 research examined co-administration with semaglutide in type 2 diabetes. These data position cagrilintide as a bridge between short-acting pramlintide and today's expansion of the class. AllPeptides.eu already has a separate educational cagrilintide reference page, while this article focuses on the class as a whole.

Petrelintide, also known as ZP8396, is a stable, long-acting human amylin analogue in clinical development by Zealand Pharma. A 2026 publication covering two randomised, controlled Phase 1 trials reported a half-life of approximately 10 days and, in the multiple-dose trial, bodyweight reduction of up to 8.6% after 16 weeks; this was an outcome in the studied research arms, not guidance for use. A separate Journal of Medicinal Chemistry paper describes its molecular development as a potent, stable, long-acting analogue. The wider programme includes NCT07076030 for pharmacokinetics in renal impairment, NCT07682818 in hepatic impairment, and the Phase 2 NCT07589686 with enicepatide. The registrations document the design of subsequent research questions, while the published Phase 1 data provide early human evidence.

Eloralintide, code-named LY3841136, is being developed by Eli Lilly as a selective amylin receptor agonist. In the published Phase 1 NCT05295940, the 4 mg and 12 mg single-dose arms had mean week-4 bodyweight changes of -2.5% and -4.4%, respectively, versus +0.6% with placebo. In the published Phase 2 NCT06230523 with 263 participants, mean changes at 48 weeks were -9% in the 1 mg arm, -12% at 3 mg, -18% at 6 mg, -20% at 9 mg, -20% in the 6-9 mg escalation arm, and -16% in the 3-9 mg escalation arm, versus -0.4% with placebo. These are outcomes from the specified trials, not dosing guidance. Development then expanded into a broad Phase 3 programme: NCT07321886 with 1,980 participants, NCT07392190 with 900, NCT07369011 with 800, and NCT07353931 with 900 started in February 2026, while NCT07282600 with 1,035 participants had started in December 2025. Taken together, ENLIGHTEN spans obesity or overweight with and without type 2 diabetes, persistent obesity during weekly incretin treatment, obstructive sleep apnoea, and knee osteoarthritis.

Eloralintide now has published Phase 1 clinical proof-of-concept data and published 48-week Phase 2 results. The remaining uncertainty concerns outcomes from the Phase 3 ENLIGHTEN programme, which have not yet been published. ClinicalTrials.gov records document the protocols, populations and estimated enrolment of those studies, but they cannot predict their results. The early clinical evidence is therefore real, while conclusions about confirmatory efficacy, safety across broader populations, or comparisons with approved medicines must await the Phase 3 data. For a detailed read on eloralintide's amylin mechanism, the dose arms that were studied and its current research status, see the full eloralintide research deep-dive.

The complementarity of amylin and incretin biology has moved from mechanistic hypothesis into clinical study design. Published data exist for cagrilintide co-administered with semaglutide. For eloralintide, NCT06916065 was a Phase 1 study that included eloralintide alone and with tirzepatide. For petrelintide, NCT07589686 examines co-administration with enicepatide. The shared research question is whether distinct satiety and metabolic-signalling axes can be combined. This is not a recommendation to combine or use these agents, and conclusions cannot precede the results.

Pramlintide is the approved, first-generation reference point with a short half-life. Cagrilintide represents the transition to a long-acting analogue with published early and combination clinical data. Petrelintide is in development through studies that include special populations and co-administration with another investigational agent. Eloralintide has entered a broad Phase 3 programme spanning obesity, type 2 diabetes and related comorbidities. The shared word 'amylin' does not make them interchangeable: they differ in pharmacokinetics, regulatory status, development design and available evidence.

Current class reviews (PMID: 41747885 and PMID: 42452898) also include MET-233i, ABBV-295 and AZD6234, as well as zenagamtide and amycretin in the broader landscape of amylin-related agents and combination approaches. Development stage and available evidence are not equivalent across these programmes. AllPeptides.eu already has separate educational coverage of amycretin.

The amylin class is emerging alongside GLP-1 because it offers a different biological entry point into satiety and postprandial regulation. Pramlintide established the first regulatory and pharmacological foundation, cagrilintide demonstrated the transition to long action, and petrelintide and eloralintide are now broadening the research field. The scientific significance lies in their differences and in the quality of both published and forthcoming data, not in premature promises. All references here are educational, bibliographic and Research Use Only.